Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002680 · ClinicalTrials.gov registry record · Phase 2
Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00002680 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 40 participants.
The verdict
NCT00002680, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of sequential high-dose chemotherapy followed by peripheral stem cell transplantation in treating patients with metastatic breast cancer that is responding to chemotherapy.
Interventions
- DRUG cyclophosphamide
- DRUG melphalan
- BIOLOGICAL filgrastim
- DRUG tamoxifen citrate
- DRUG megestrol acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1994-02 |
| Est. Completion | 2000-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002680
The ClinicalTrials.gov registry entry for NCT00002680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002680 about?
NCT00002680 is a clinical study titled "Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of sequential high-dose chemotherapy...
What is the current status of trial NCT00002680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1994-02. Estimated completion is 2000-12.
What interventions are being tested in trial NCT00002680?
The interventions under investigation include: cyclophosphamide (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), tamoxifen citrate (DRUG), megestrol acetate (DRUG).
Who is sponsoring clinical trial NCT00002680?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.